Combination therapy of intravitreal ranibizumab and sub-tenon triamcinolone for treatment of resistant diabetic macular edema: a clinical study in Egypt
Abstract Background Among those aged 20–74 in industrialized countries, diabetic retinopathy (DR) is the main cause of visual impairment. Diabetic macular edema (DME) is the leading cause of blindness in people with DR. DME that is resistant to therapy is now being treated with a number of different...
Saved in:
Main Authors: | Hossam Eldin M. A. Khalil, Hazem E. Haroun, Alaa A. I. Shalan, Waleed M. Mahran |
---|---|
Format: | Article |
Language: | English |
Published: |
SpringerOpen
2025-01-01
|
Series: | Beni-Suef University Journal of Basic and Applied Sciences |
Subjects: | |
Online Access: | https://doi.org/10.1186/s43088-025-00598-x |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Suprachoroidal Versus Intravitreal Injection of Triamcinolone Acetonide As Primary Treatment For Diabetic Macular Edema
by: Fatima Shafqat Khan, et al.
Published: (2023-12-01) -
Clinical Evaluation of Faricimab in Real-World Diabetic Macular Edema in India- A Multicenter Observational Study
by: Chakraborty D, et al.
Published: (2025-01-01) -
Efficacy & safety of brolucizumab 6.0 mg versus 3.6 mg in diabetic macular edema
by: Sanjay Kumar Mishra, et al.
Published: (2025-01-01) -
Application of deep learning algorithm for judicious use of anti-VEGF in diabetic macular edema
by: Anwesa Mondal, et al.
Published: (2025-02-01) -
Dosing intervals in Comparison of one-year real-world outcomes between red (670 nm) subthreshold micropulse laser treatment and intravitreal aflibercept injection for treatment-naïve diabetic macular edema
by: Kai Ching Peter Leung, et al.
Published: (2025-02-01)